Iradimed Depreciation And Amortization vs Income Before Tax Analysis

IRMD Stock

USD 42.65 0.50 1.19%

Iradimed financial indicator trend analysis is infinitely more than just investigating Iradimed recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iradimed is a good investment. Please check the relationship between Iradimed Depreciation And Amortization and its Income Before Tax accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Depreciation And Amortization vs Income Before Tax

Depreciation And Amortization vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iradimed Depreciation And Amortization account and Income Before Tax. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Iradimed's Depreciation And Amortization and Income Before Tax is -0.24. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Iradimed Co, assuming nothing else is changed. The correlation between historical values of Iradimed's Depreciation And Amortization and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Iradimed Co are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Depreciation And Amortization i.e., Iradimed's Depreciation And Amortization and Income Before Tax go up and down completely randomly.

Correlation Coefficient

-0.24

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Iradimed income statement and is an important metric when analyzing Iradimed profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Iradimed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iradimed current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

At present, Iradimed's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 51.10, whereas Selling General Administrative is forecasted to decline to about 9.3 M.

	2021	2022	2023	2024 (projected)
Gross Profit	32.0M	41.3M	50.2M	27.1M
Total Revenue	41.8M	53.3M	65.6M	35.1M

Gross Profit Total Revenue

Iradimed fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.59	0.55	0.68	1.0	0.78	0.68	0.94	-0.97	0.99	0.77	0.98	0.76	0.52	0.42	0.98	0.78	0.94	0.87	-0.13	0.91	0.63	0.82	0.95	0.79	0.7
Short Long Term Debt Total	0.59		0.06	0.19	0.62	0.71	0.24	0.46	-0.53	0.56	0.42	0.54	0.29	0.04	0.39	0.66	0.28	0.77	0.64	0.68	0.52	0.24	0.44	0.71	0.3	0.18
Other Current Liab	0.55	0.06		0.97	0.5	0.26	0.95	0.46	-0.57	0.48	0.58	0.47	0.93	0.96	-0.14	0.44	0.81	0.55	0.56	-0.43	0.46	0.95	0.8	0.51	0.92	0.96
Total Current Liabilities	0.68	0.19	0.97		0.65	0.42	0.95	0.64	-0.7	0.64	0.7	0.6	0.97	0.96	-0.05	0.59	0.9	0.67	0.69	-0.37	0.58	0.98	0.88	0.63	0.98	0.99
Total Stockholder Equity	1.0	0.62	0.5	0.65		0.78	0.65	0.93	-0.98	0.99	0.75	0.99	0.73	0.48	0.45	0.99	0.76	0.94	0.87	-0.1	0.9	0.6	0.81	0.96	0.76	0.67
Other Liab	0.78	0.71	0.26	0.42	0.78		0.51	0.73	-0.75	0.81	0.44	0.75	0.57	0.22	0.62	0.8	0.49	0.74	0.76	0.16	0.89	0.43	0.63	0.67	0.58	0.43
Property Plant And Equipment Net	0.68	0.24	0.95	0.95	0.65	0.51		0.57	-0.7	0.63	0.57	0.61	0.98	0.89	0.1	0.6	0.8	0.68	0.69	-0.34	0.67	0.95	0.89	0.63	0.97	0.96
Current Deferred Revenue	0.94	0.46	0.46	0.64	0.93	0.73	0.57		-0.92	0.96	0.74	0.93	0.68	0.5	0.37	0.91	0.79	0.8	0.79	-0.22	0.82	0.58	0.76	0.83	0.73	0.65
Net Debt	-0.97	-0.53	-0.57	-0.7	-0.98	-0.75	-0.7	-0.92		-0.97	-0.68	-0.99	-0.77	-0.53	-0.44	-0.98	-0.79	-0.88	-0.88	0.23	-0.89	-0.63	-0.85	-0.92	-0.8	-0.72
Retained Earnings	0.99	0.56	0.48	0.64	0.99	0.81	0.63	0.96	-0.97		0.72	0.99	0.72	0.46	0.46	0.98	0.75	0.88	0.86	-0.17	0.92	0.58	0.8	0.9	0.76	0.65
Accounts Payable	0.77	0.42	0.58	0.7	0.75	0.44	0.57	0.74	-0.68	0.72		0.68	0.67	0.68	0.0	0.68	0.86	0.78	0.71	-0.07	0.57	0.67	0.6	0.76	0.7	0.71
Cash	0.98	0.54	0.47	0.6	0.99	0.75	0.61	0.93	-0.99	0.99	0.68		0.69	0.43	0.48	0.99	0.72	0.87	0.84	-0.21	0.91	0.53	0.78	0.92	0.73	0.63
Non Current Assets Total	0.76	0.29	0.93	0.97	0.73	0.57	0.98	0.68	-0.77	0.72	0.67	0.69		0.9	0.13	0.68	0.89	0.74	0.75	-0.34	0.72	0.96	0.91	0.69	1.0	0.98
Non Currrent Assets Other	0.52	0.04	0.96	0.96	0.48	0.22	0.89	0.5	-0.53	0.46	0.68	0.43	0.9		-0.18	0.41	0.87	0.54	0.55	-0.39	0.39	0.96	0.77	0.49	0.9	0.96
Other Assets	0.42	0.39	-0.14	-0.05	0.45	0.62	0.1	0.37	-0.44	0.46	0.0	0.48	0.13	-0.18		0.49	0.04	0.35	0.35	0.04	0.59	-0.06	0.22	0.39	0.12	0.02
Cash And Short Term Investments	0.98	0.66	0.44	0.59	0.99	0.8	0.6	0.91	-0.98	0.98	0.68	0.99	0.68	0.41	0.49		0.71	0.92	0.87	-0.07	0.89	0.54	0.79	0.95	0.71	0.61
Net Receivables	0.78	0.28	0.81	0.9	0.76	0.49	0.8	0.79	-0.79	0.75	0.86	0.72	0.89	0.87	0.04	0.71		0.73	0.76	-0.34	0.65	0.85	0.78	0.73	0.91	0.92
Common Stock Total Equity	0.94	0.77	0.55	0.67	0.94	0.74	0.68	0.8	-0.88	0.88	0.78	0.87	0.74	0.54	0.35	0.92	0.73		0.86	0.15	0.8	0.67	0.82	0.98	0.75	0.68
Common Stock Shares Outstanding	0.87	0.64	0.56	0.69	0.87	0.76	0.69	0.79	-0.88	0.86	0.71	0.84	0.75	0.55	0.35	0.87	0.76	0.86		0.01	0.76	0.68	0.81	0.85	0.78	0.69
Short Term Investments	-0.13	0.68	-0.43	-0.37	-0.1	0.16	-0.34	-0.22	0.23	-0.17	-0.07	-0.21	-0.34	-0.39	0.04	-0.07	-0.34	0.15	0.01		-0.19	-0.25	-0.18	0.04	-0.36	-0.41
Non Current Liabilities Total	0.91	0.52	0.46	0.58	0.9	0.89	0.67	0.82	-0.89	0.92	0.57	0.91	0.72	0.39	0.59	0.89	0.65	0.8	0.76	-0.19		0.53	0.72	0.8	0.74	0.62
Inventory	0.63	0.24	0.95	0.98	0.6	0.43	0.95	0.58	-0.63	0.58	0.67	0.53	0.96	0.96	-0.06	0.54	0.85	0.67	0.68	-0.25	0.53		0.88	0.59	0.95	0.97
Other Current Assets	0.82	0.44	0.8	0.88	0.81	0.63	0.89	0.76	-0.85	0.8	0.6	0.78	0.91	0.77	0.22	0.79	0.78	0.82	0.81	-0.18	0.72	0.88		0.79	0.92	0.87
Other Stockholder Equity	0.95	0.71	0.51	0.63	0.96	0.67	0.63	0.83	-0.92	0.9	0.76	0.92	0.69	0.49	0.39	0.95	0.73	0.98	0.85	0.04	0.8	0.59	0.79		0.72	0.65
Total Liab	0.79	0.3	0.92	0.98	0.76	0.58	0.97	0.73	-0.8	0.76	0.7	0.73	1.0	0.9	0.12	0.71	0.91	0.75	0.78	-0.36	0.74	0.95	0.92	0.72		0.98
Property Plant And Equipment Gross	0.7	0.18	0.96	0.99	0.67	0.43	0.96	0.65	-0.72	0.65	0.71	0.63	0.98	0.96	0.02	0.61	0.92	0.68	0.69	-0.41	0.62	0.97	0.87	0.65	0.98

Click cells to compare fundamentals

Iradimed Account Relationship Matchups

Iradimed fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	66.7M	71.1M	82.9M	85.5M	92.2M	54.5M
Other Current Liab	3.0M	2.1M	3.2M	3.1M	11.5M	12.0M
Total Current Liabilities	5.9M	4.9M	6.8M	8.6M	16.3M	17.1M
Total Stockholder Equity	55.5M	61.4M	72.2M	73.7M	71.4M	46.1M
Other Liab	2.6M	2.3M	1.7M	1.4M	1.6M	1.4M
Property Plant And Equipment Net	5.0M	4.8M	4.6M	2.4M	11.3M	11.9M
Current Deferred Revenue	1.7M	1.9M	2.6M	3.4M	2.6M	1.7M
Net Debt	(40.5M)	(47.4M)	(59.5M)	(55.8M)	(47.7M)	(45.3M)
Retained Earnings	36.3M	37.7M	47.0M	47.3M	43.3M	27.5M
Accounts Payable	993.7K	657.1K	782.9K	1.8M	1.9M	1.0M
Cash	43.5M	50.1M	62.0M	58.0M	49.8M	33.0M
Non Current Assets Total	7.8M	7.3M	6.6M	7.3M	16.2M	17.0M
Non Currrent Assets Other	232.0K	262.0K	201.3K	2.2M	4.8M	5.1M
Other Assets	1.9M	6.4M	966.4K	1.3M	1.0	0.95
Cash And Short Term Investments	46.3M	52.0M	62.5M	58.0M	49.8M	37.0M
Net Receivables	7.3M	4.6M	5.1M	13.3M	12.2M	12.8M
Common Stock Total Equity	1.2K	1.2K	1.3K	1.3K	1.4K	1.2K
Common Stock Shares Outstanding	12.3M	12.4M	12.6M	12.6M	12.7M	13.0M
Short Term Investments	8.1M	6.3M	2.8M	1.9M	501.9K	0.0
Liabilities And Stockholders Equity	66.7M	71.1M	82.9M	85.5M	92.2M	54.5M
Non Current Liabilities Total	5.3M	4.8M	3.9M	3.3M	4.4M	2.5M
Inventory	3.6M	3.9M	4.3M	5.4M	12.8M	13.5M
Other Current Assets	407.8K	771.7K	1.0M	631.0K	1.2M	1.3M
Other Stockholder Equity	19.2M	23.7M	25.2M	26.4M	28.2M	18.5M
Total Liab	11.2M	9.7M	10.7M	11.8M	20.7M	21.8M
Property Plant And Equipment Gross	5.0M	4.8M	4.6M	8.0M	15.4M	16.2M
Total Current Assets	59.0M	63.7M	76.2M	78.2M	76.0M	49.0M
Accumulated Other Comprehensive Income	(42.2K)	30.4K	37.1K	17.0K	19.6K	20.5K
Short Term Debt	240.8K	255.7K	276.6K	293.5K	428.0K	355.5K
Intangible Assets	860.1K	960.9K	1.1M	2.1M	2.5M	2.6M
Common Stock	1.2K	1.2K	1.3K	1.3K	1.3K	1.2K
Property Plant Equipment	2.1M	2.1M	4.6M	2.4M	2.8M	1.9M
Net Tangible Assets	54.7M	60.4M	71.1M	71.6M	82.3M	50.6M
Retained Earnings Total Equity	36.3M	37.7M	47.0M	47.3M	54.4M	30.9M
Capital Surpluse	19.2M	23.7M	25.2M	26.4M	30.4M	20.7M
Net Invested Capital	55.5M	61.4M	72.2M	73.7M	71.4M	64.3M
Net Working Capital	53.1M	58.8M	69.4M	69.6M	59.7M	60.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:

How To Invest In Iradimed

Details

Is Iradimed Stock a good investment?

Details

What is Iradimed's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Iradimed Stock analysis

When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.

	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Transaction History View history of all your transactions and understand their impact on performance
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Commodity Directory Find actively traded commodities issued by global exchanges
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.185

Dividend Share

0.15

Earnings Share

1.4

Revenue Per Share

5.363

Quarterly Revenue Growth

0.137

The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iradimed Depreciation And Amortization vs Income Before Tax Analysis

Depreciation And Amortization vs Income Before Tax

Depreciation And Amortization vs Income Before Tax Correlation Analysis

Correlation Coefficient

Depreciation And Amortization

Income Before Tax

Iradimed fundamental ratios Correlations

Iradimed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iradimed fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Iradimed Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Non Current Assets Total
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Current Liabilities
Retained Earnings	+ 0.99	Total Stockholder Equity
Cash	+ 0.99	Total Stockholder Equity

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Other Stockholder Equity	- 0.92	Net Debt